In Person & Webcast Archives - Research to Practice

A Multitumor CME/MOC-, NCPD- and ACPE-Accredited Educational Conference Developed in Partnership with Florida Cancer Specialists & Research Institute

Note from the Moderator
This coming April 23^rd marks the return of our annual National General Medical Oncology Summit. To include community perspectives, we are pleased to be partnering again with Florida Cancer Specialists & Research Institute for this one-of-a-kind offering that will span 3 days and feature a stellar multidisciplinary faculty panel of clinical investigators and a unique blend of short didactic presentations, lively moderated panel discussions and dedicated Q&A sessions. The conference’s educational design and the topics that will be discussed offer interested clinicians access to the in-depth perspectives of some of the top minds in the field regarding significant new datasets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with cancer. We hope you will join us in sunny Florida for a learning experience unlike any other out there.

Program Schedule — Eastern Time
Friday to Sunday, April 23 to 25, 2027

Location
The Ritz-Carlton Orlando, Grande Lakes
4012 Central Florida Parkway
Orlando, Florida
Hotel Phone: (407) 206-2400

Meeting Room
Ritz Carlton Ballroom (Salons I-III) — Lobby Level

Room Reservations
A special discounted room rate of $429 per night (plus applicable tax and discounted resort fee) is available to conference attendees at The Ritz-Carlton Orlando, Grande Lakes. Please see the Location tab for details.

No registration fee. Preregistration is required for in-person attendance in Orlando as seating is limited.

Moderator

Neil Love

MD

Research To Practice

Miami, Florida

Faculty to be announced.

Join us from Friday, April 23 to Sunday, April 25, 2027.

Preliminary Agenda
A detailed agenda and speaker information will be made available in the coming months. Times and schedule are subject to change.

Friday, April 23rd
6:30 PM – 7:00 PM			    Welcome Reception
7:00 PM – 9:00 PM			    Keynote Session

Saturday, April 24th 
7:00 AM – 7:45 AM			    Breakfast
7:45 AM – 12:30 PM			    Morning General Session
12:30 PM – 1:15 PM			    Lunch
1:15 PM – 5:30 PM			    Afternoon Breakout Sessions 

Sunday, April 25th 
7:00 AM – 7:45 AM			    Breakfast
7:45 AM – 12:15 PM			    Morning General Session
12:15 PM – 1:00 PM			    Lunch
1:00 PM – 3:30 PM			    Afternoon General Session

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

Learning Objectives
To be announced.

CE Credit
CME, ABIM MOC, ABS and ACPE credit information will be given to each participant as part of the meeting course materials.

NCPD Credit
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

CME Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Designation Statement
To be announced.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn Medical Knowledge MOC points toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

NCPD Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Number of Contact Hours Awarded
To be announced.

ONCC/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be remitted for ONCC/ILNA approval.

ACPE Accreditation Statement
The University of Texas at Austin College of Pharmacy Continuing Professional Development will provide the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

ACPE Credit Designation Statement
To be announced.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

FACULTY
To be announced.

MODERATOR
Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

Research To Practice CME/NCPD/ACPE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

The Ritz-Carlton Orlando, Grande Lakes
4012 Central Florida Pkwy
Orlando, FL 32837
Hotel Phone: (407) 206-2400

Meeting Room
Ritz Carlton Ballroom (Salons I-III) — Lobby Level

Room Reservations
A special discounted room rate of $429 per night and a discounted resort fee of $40 per night, plus applicable taxes, are available to conference attendees at The Ritz-Carlton Orlando, Grande Lakes.

Instructions on how to secure hotel accommodations will be included in the confirmation email after you have completed registration. Florida Cancer Specialists members, please contact FCS directly to confirm accommodations.

Room reservations must be made by Wednesday, March 24, 2027. A limited number of rooms are available, and we encourage you to make your reservations early. After Wednesday, March 24^th, the hotel will offer the best rates based on room availability.

Parking
Discounted valet parking is available at $46.40 plus applicable taxes:

Overnight guests: The discounted rate will be automatically applied at checkout for attendees staying within the conference hotel block.
Daily guests: Vouchers will be provided at the registration desk each day of the conference.

Self-parking is not available at the hotel.

All parking rates are subject to change.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

Register for webcast

This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

No registration fee is charged for this event. Preregistration is required as seating is limited.

At this time, in-person registration for this educational activity is limited to practicing clinicians. For all other professionals,* we are unable to confirm seating at this time. If you would like to be added to our standby list, please click here to complete the Standby Registration form. We will notify you should seats become available.

Virtual registration is open to all professionals. Please complete the Webcast Registration form to register for virtual attendance.

* Individuals employed by for-profit organizations, including financial institutions and biotech or pharmaceutical companies.

Registration

Name(Required)

First Last

Email(Required)

Address(Required)

City State / Province / Region Country

Are you a Florida Cancer Specialists member?(Required)

Yes

No

Clinical background

Degree(Required)

Specialty(Required)

If you are a clinician, which of the following best describes your practice setting?(Required)

Medical/Practice License #

How did you learn about this symposium?

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Thank you for your interest. At this time registration to attend this activity in person is closed to industry professionals and nonclinicians. Please provide your contact information below if you would like to be notified should seats become available, and we will be happy to alert you. If you have any further questions, please contact us at Meetings@ResearchToPractice.com.

Standby Registration

Name(Required)

First Last

Email(Required)

Professional Designation(Required)

Company/Institution(Required)

Address(Required)

City State / Province / Region Country

How did you learn about this symposium?

Notes

A CME Satellite Symposium

Program Schedule — Central Time
Thursday, December 10, 2026
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:00 PM — Educational Meeting

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room
To be announced.

No registration fee. Preregistration is required for in-person attendance in San Antonio as seating is limited.

Faculty

Adam M Brufsky

MD, PhD

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania

Professor of Medicine, Department of Medicine

Faculty

Charles E Geyer Jr

MD

UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Professor of Medicine, Division Chief, Malignant Hematology and Medical Oncology

NSABP Foundation, Pittsburgh, Pennsylvania

Chief Scientific Officer

NRG Oncology, Philadelphia, Pennsylvania

Associate Group Chair

Faculty

Matthew P Goetz

MD

Mayo Clinic, Rochester, Minnesota

Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD, Professor of Oncology and Pharmacology, Enterprise Deputy Director, Translational Research, Director, Mayo Clinic Breast Cancer SPORE

Moderator

Rita Nanda

MD

The University of Chicago, Chicago, Illinois

Director, Breast Oncology, Associate Professor of Medicine, Section of Hematology/Oncology

This symposium is sponsored by Research To Practice and supported by grants from Agendia Inc, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Exact Sciences Corporation, Genentech, a member of the Roche Group, and Merck. This is not an official program of the San Antonio Breast Cancer Symposium®.

Join us on Thursday, December 10^th from 7:00 PM to 9:00 PM central time (8:00 PM to 10:00 PM eastern time).

Module 1: Integration of Adjuvant CDK4/6 Inhibitor Therapy into the Current Management of High-Risk, Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer

Clinical and biological factors (eg, age/menopausal status, tumor size/grade, nodal involvement, genomic assay results, comorbidities) affecting the choice of adjuvant therapy for HR-positive, HER2-negative localized breast cancer; rationale for the addition of CDK4/6 inhibitors to standard adjuvant endocrine therapy for high-risk disease
Long-term outcomes, including overall survival (OS) data, from the Phase III monarchE trial evaluating the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer
Extended follow-up with adjuvant ribociclib and endocrine therapy compared to endocrine therapy alone in the Phase III NATALEE trial
FDA-approved indications and identification of appropriate candidates for adjuvant abemaciclib and ribociclib
Other relevant studies (eg, the Phase II TRADE trial) attempting to optimize the use of CDK4/6 inhibitors in the adjuvant setting
Available data with and ongoing studies evaluating CDK4/6 inhibitors as neoadjuvant therapy for localized HR-positive breast cancer

Module 2: Available Data with and Practical Application of PARP Inhibition as Adjuvant Therapy for Patients with HR-Positive Localized Breast Cancer

Incidence of germline BRCA1/2 mutations and other homologous recombination repair (HRR) gene mutations in patients with HR-positive, HER2-negative breast cancer; optimal approach to genetic testing
Key findings, including OS data, from the Phase III OlympiA trial assessing adjuvant olaparib versus placebo for patients with high-risk, HER2-negative breast cancer and germline BRCA1/2 mutations
Optimal selection of candidates with high-risk, HR-positive, HER2-negative breast cancer with germline BRCA mutations for adjuvant olaparib; role, if any, for patients with other germline or somatic HRR alterations
Early data with and ongoing evaluation of PARP inhibitors in the neoadjuvant setting
Incidence, severity and management of toxicities associated with PARP inhibitors in the localized setting

Module 3: Potential Use of Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer

Rationale for the investigation of oral SERDs as adjuvant therapy for patients with HR-positive, HER2-negative localized breast cancer
Design, eligibility criteria and primary and secondary endpoints of the Phase III lidERA study evaluating adjuvant giredestrant versus physician’s choice of adjuvant endocrine monotherapy for patients with HR-positive, HER2-negative localized breast cancer
Improvement in invasive disease-free survival and other key efficacy outcomes documented with adjuvant giredestrant in lidERA
Tolerability profile of giredestrant versus standard adjuvant endocrine therapy in lidERA
Potential clinical role of adjuvant giredestrant for patients with HR-positive, HER2-negative localized breast cancer
Ongoing Phase III trials (eg, ELEGANT, TREAT ctDNA, EMBER-4, CAMBRIA-1, CAMBRIA-2) of other oral SERDs in the adjuvant or neoadjuvant setting

Module 4: Risk Assessment and Genomic Assays for Treatment Decision-Making in HR-Positive, HER2-Negative Localized Breast Cancer

Similarities and differences among available genomic assays (eg, Oncotype DX^®, MammaPrint^®, Prosigna^®, EndoPredict^®, Endocrine Activity Index^®, Breast Cancer Index^®)
Key studies informing the use of the 21-gene Recurrence Score^® (RS) to guide neoadjuvant and adjuvant treatment decision-making for patients with HR-positive, HER2-negative localized breast cancer
Clinical research supporting the utility of the 70-gene signature in preoperative and adjuvant treatment planning for patients with HR-positive, HER2- negative localized breast cancer
Current clinical utility of genetic tests and prognostic tools that complement available genomic assays (eg, the RSClin educational tool in concert with the 21-gene RS, the BluePrint^® molecular subtyping test in concert with the 70-gene signature)
Published research supporting the use of the Breast Cancer Index to inform extended adjuvant endocrine therapy decision-making for patients with HR-positive localized breast cancer

Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

Understand how various clinical and biological factors, including age/menopausal status, tumor size/grade and nodal involvement affect a patient’s risk of recurrence, and use this information to personalize the selection of adjuvant systemic therapy for individuals with newly diagnosed hormone receptor (HR)-positive, HER2-negative breast cancer.
Appraise the scientific justification for, available data with and potential clinical role of oral selective estrogen receptor degraders (SERDs) as adjuvant treatment for localized estrogen receptor-positive, HER2-negative breast cancer.
Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant therapy with one of these agents would be appropriate.
Recognize adverse events and other common side effects associated with different CDK4/6 inhibitors for localized breast cancer, and tailor therapy for individuals with preexisting medical conditions and relevant comorbidities.
Appreciate the incidence of BRCA1/2 and other DNA damage repair mutations in patients with localized HR-positive breast cancer, and assess the role of adjuvant PARP inhibition for individuals harboring these abnormalities.
Assess the similarities and differences among the various genomic assays with established prognostic and predictive utility for HR-positive localized breast cancer, and consider available research findings informing the use of these tests.

CE Credit
CME credit information will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Brufsky — Consulting Agreements: Agendia Inc, AstraZeneca Pharmaceuticals LP, BriaCell, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc; Contracted Research: Agendia Inc; Stock Options/Stock — Public Companies: Celcuity; Stock Options — Private Companies: Ataraxis. Dr Geyer — Contracted Research: Abbott, Artera, AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Daiichi Sankyo Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group. Dr Goetz — Advisory Committees: AstraZeneca Pharmaceuticals LP, AstraZeneca UK, Ataraxis, BeOne, Biotheranostics Inc, A Hologic Company, Biotheryx, EcoR1 Capital LLC, Genentech, a member of the Roche Group, Incyclix Bio, Puma Biotechnology Inc, Rna Diagnostics; Consulting Agreements: Genentech, a member of the Roche Group, Lilly, Novartis, Stemline Therapeutics Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Biotheryx, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Sermonix Pharmaceuticals, SimBioSys; Data and Safety Monitoring Boards/Committees: Pfizer Inc; Personal Fees for CME Activities: DAVA Oncology; Nonrelevant Financial Relationships: AXIS Medical Education Inc, BroadcastMed, eChinaHealth, IDEOlogy Health, MJH Life Sciences, PeerView, Physician Education Resource (PER), Total Health Conferencing.

MODERATOR
Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Relay Therapeutics.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Agendia Inc, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Exact Sciences Corporation, Genentech, a member of the Roche Group, and Merck.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
To be announced.

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 San Antonio Breast Cancer Symposium is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

Register for webcast

This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

No registration fee is charged for this event. Preregistration is required as seating is limited.

Please note that registration for this event is independent of registration for the San Antonio Breast Cancer Symposium.

I am a:(Required)

Clinician/healthcare professional

Other/industry professional